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Abstract
Background: West Nile Virus (WNV) is a mosquito-borne flavivirus that has caused ongoing seasonal epidemics in
the United States since 1999. It is estimated that ≤1% of WNV-infected patients will develop neuroinvasive disease
(West Nile encephalitis and/or myelitis) that can result in debilitating morbidities and long-term sequelae. It is
essential to collect longitudinal information about the recovery process and to characterize predicative factors
that may assist in therapeutic decision-making in the future.
Methods: We report a longitudinal study of the neurological outcomes (as measured by neurological
examination, Glascow Coma Scale, and Modified Mini-Mental State Examination) for 55 subjects with WNV neuroinvasive
disease (confirmed by positive CSF IgM) assessed on day 7, at discharge, and on days 14, 30, and 90. The neurological
outcome measures were coma (presence and degree), global cognitive status, presence of cranial neuropathy,
tremors and/or weakness.
Results: At initial clinical presentation 93% presented with a significant neurological deficit (49% with weakness,
35% with tremor, and 16% with cranial neuropathy). The number of patients with a cognitive deficit fell from 25
at initial evaluation to 9 at their last evaluation. Cranial neuropathy was present in 9 at onset and in only 4
patients at study conclusion. Of the 19 patients who had a tremor at enrollment, 11 continued to exhibit a
tremor at follow-up. Seven patients died after initial enrollment in the study, with 5 of those having presented
in a coma. The factors that predict either severity or long-term recovery of neurological function include age
(older individuals were weaker at follow-up examination), gender (males recovered better from coma), and presentation
in a coma with cranial nerve deficits (had a poorer recovery particularly with regard to cognition).
Conclusions: This study represents one of the largest clinical investigations providing prospectively-acquired
neurological outcomes data among American patients with WNV central nervous system disease. The findings
show that the factors that influence prognosis from the initial presentation include age, gender, and specific
neurological deficits at onset.
Trial registration: ClinicalTrials.gov identifier: NCT00138463 and NCT00069316.
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Background
West Nile Virus (WNV), a zoonotic arbovirus of the Flavi-
viridae family, is transmitted from infected birds to humans
via mosquito vectors [1]. First identified in Uganda in 1937,
numerous outbreaks of human WNV disease have been re-
ported globally. The first cases in the United States ap-
peared in 1999, initially occurring as a localized epidemic
of encephalitis in New York City [1-3]. Subsequently, the
WNV epidemic spread across the United States, peaking at
9862 reported cases with 264 documented deaths in 2003
(CDC statistics). WNV established a relatively stable pat-
tern of endemic infection in the U.S., although there was a
resurgence in 2012, with 5674 reported cases and 286
deaths (CDC statistics).
About 70-80% of individuals infected by WNV are asymp-
tomatic and do not come to medical attention, while ap-
proximately 20-30% have “West Nile Fever” without
evidence of neurologic involvement [4-7]. Neuroinva-
sive disease accounts for less than 1% of WNV cases,
but can result in severe neurological sequelae and death
[8]. The mortality rate is between 10% and 30% for pa-
tients with neuroinvasive WNV disease, or <0.1% of all
infected patients [8,9].
The virus invades a wide range of anatomic structures
of the central nervous system (CNS) [10-12]. Neuroinva-
sive WNV disease can manifest as one of three main
clinical entities: West Nile meningitis (WNM), West
Nile encephalitis (WNE), or acute flaccid paralysis (AFP)
[13]. Myelitis with AFP can occur independently or in
conjunction with WNE. CNS disease has been associated
with changes in cognitive status, muscle weakness, motor
neuron disease (flaccid paralysis and hyporeflexia), cranial
nerve palsies (most commonly facial nerve palsy),
Guillain-Barre like syndrome (GBS), or movement disor-
ders (e.g., myoclonus, tremor, parkinsonism) [1,8,14-18].
This spectrum of clinical findings is mirrored by radio-
logic abnormalities that involve the basal ganglia, thal-
ami, cerebellum, and brain stem [19-21]. Importantly,
imaging studies may be normal or demonstrate only
nonspecific changes in patients with acute neuroinva-
sive WNV infection and are thus of limited utility for
diagnostic purposes [1,12].
Clinical signs and symptoms of disease during the
acute phase of WNV infection have only modest prog-
nostic value. The severity of acute symptoms is not an
accurate predictor of duration or extent of recovery,
which can be quite variable [4,8,10,22]. Older age (over
50 years) and medical co-morbidities have been associ-
ated with higher rate WNV-related morbidity and mor-
tality [3,23]. The variability of the degree of resolution of
neurologic disease is particularly striking. While some
initial symptoms may remit to the premorbid baseline,
others can persist for over a year after disease onset [22,24].
Most patients with WNM and no focal neurological deficits
usually recovery fully, but there are frequent subjective com-
plaints of prolonged fatigue and weakness [16,25]. Unlike
WNM, patients diagnosed with WNE have a significant
mortality rate (~20%) and those who survive are likely to ex-
perience persistent movement disorders (e.g., tremors, bra-
dykinesia) for months to years [4]. AFP has the worst overall
prognosis and a high mortality rate, which can reach 50%
when neuromuscular respiratory failure occurs [4]. Severe
residual muscle weakness is common, but improve-
ments of muscle strength have been observed within
the first 6 months to 1 year after disease onset, such
that patients can regain partial function of the para-
lyzed extremities [4,10,22,26].
While these studies have provided useful insight into the
initial neurological presentation of and subsequent recov-
ery from WNV neuroinvasive disease, prospectively
collected, longitudinal data defining the clinical course of
WNV neuroinvasive disease have been limited. These types
of studies have been difficult to perform due to the spor-
adic nature and unpredictable geographic distribution of
the WNV outbreaks. We report here a longitudinal, pro-
spective, multi-center evaluation of neurologic outcomes
of patients with neuroinvasive WNV disease in the U.S.
Methods
The current report is derived from a randomized, double-
blinded, placebo-controlled clinical trial performed by the
National Institute of Allergy and Infectious Diseases
(NIAID) Collaborative Antiviral Study Group (CASG)
to assess the safety and potential therapeutic utility of
passive immunotherapy in patient with WNV neuro-
logic disease. Patients were randomized to receive high-
titer WNV immunoglobulin (Omr-IgG-amTM), intravenous
immune globulin (Polygam® S/D), or normal saline at a ra-
tio of 3:1:1.
This clinical trial was conducted between the Fall of
2003 and the Fall of 2006 at 43 sites in the U.S. and
Canada and was approved by local institutional review
boards (the CASG Central Unit IRB is as follows: the UAB
Institutional Review Board for Human Use, 701 20th Street
South, AB 407 Birmingham, AL 35294–0104; trial registra-
tion: NCT00138463 CASG 211 and NCT00069316 CASG
210). This report will focus on a detailed evaluation of
neurologic presentations and outcomes while results re-
lated to the therapeutic interventions will be published
separately.
Enrollment criteria
Enrollment was limited to patients with suspected WNV
disease based on clinical findings (with subsequent con-
firmatory diagnostic testing) or patients in whom WNV
disease had already been proven. For purposes of this
study, laboratory diagnosis of WNV infection was estab-
lished by either a positive serum or cerebrospinal fluid
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(CSF) anti-WNV IgM serologic assay. WNV serologic
testing for all subjects was performed at the Clinical
Virology Laboratory at the University of Alabama at
Birmingham using the Focus Technologies ELISA meth-
odology. No additional confirmatory diagnostic testing
was undertaken. The subjects provided written informed
consent (or consent was provided by a legal representa-
tive). Subjects were enrolled based on one of two eligibility
categories:
1. Hospitalized patients greater than age 18 with
encephalitis and/or myelitis presenting as a new
neurologic abnormality (asymmetric extremity
weakness without sensory abnormality, other
neurologic abnormality, or altered level of
consciousness), plus fever within the previous
4 days; and CSF examination within the previous
96 hours demonstrating an absence of organisms by
routine microbiologic testing (including polymerase
chain reaction [PCR] test for herpes simplex virus),
WBCs > =4 per mm3 (corrected for significant red
blood cell contamination), and ratio of CSF: plasma
glucose of ≥ 40% (CSF glucose/plasma glucose ≥ 0.4).
The etiology of illness was subsequently confirmed
to be caused by WNV by specific serologic testing,
as above.
2. Hospitalized patients without encephalitis and/or
myelitis who met the following criteria: a positive
IgM serology for WNV (performed at the local site
laboratory; subsequent confirmation at the study
central laboratory required) in blood or
cerebrospinal fluid, and clinical illness compatible
with WNV infection as defined by occurrence of ≥ 3
of the following findings during the preceding ≤ 10 days
(diarrhea; headache, fever > 38 ºC; nausea and/or
vomiting; myalgias and/or arthralgias; nuchal rigidity;
macular or papular rash, new neurological abnormality);
and a risk factor for the development of WNV
neurologic disease as defined by being older than
40 years of age, or being older than 18 and
immunocompromised.
Exclusion criteria included: unable to provide informed
consent; history of intolerance (including anaphylaxis) to
intravenous immunoglobulin (IVIg) or related compounds;
known history of IgA deficiency; known history of hyper-
sensitivity to maltose; history of hyperviscosity syndrome;
congestive heart failure as defined as Class III or IV by the
New York Heart Association Classification; serum creatin-
ine > 2.5 mg/dL or requirement of hemodialysis; another
plausible explanation for clinical findings (such as struc-
tural brain lesion, cerebrovascular accident, or other infec-
tious disease, including confirmed infections with other
flaviviruses); pregnant or breastfeeding.
Study oversight
The clinical trial was supported by the National Institute
of Allergy and Infectious Diseases under an Investiga-
tional New Drug Application that was held by the spon-
soring Institution. All patients were clinically managed
at the local participating institutions. All data were re-
corded on standardized case record forms. Data verification
was performed by an independent monitor to guarantee ac-
curacy and completeness.
Stopping rules were built into this study based on the
number of observed serious adverse events. An inde-
pendent Data Safety and Monitory Board (DSMB) reviewed
all clinical data, including the neurologic assessments pre-
sented herein. With guidance from the DSMB, subject en-
rollment was terminated in 2006 due to: 1). slower-than-
expected enrollment; 2). expiration of the Omr-IgG-am™
study product; and 3). inability to procure sufficient quan-
tities of WNV IgG-free IVIg of U.S. origin to use as a
control.
Study design
At the time of randomization, each of the participants
underwent measurement of vital signs, a general physical
examination and, and a detailed neurological evaluation
which included determination of scores on the Glasgow
Coma Scale (GCS) and the adapted Glasgow Outcome
Score (GOS), the Modified Mini-Mental Status test (3MS),
the Modified Rankin Scale (MRS), and the Barthel Index
(BI). Safety laboratories and confirmatory CSF were ob-
tained followed by initiation of study medication according
to the randomization schedule. The above-listed assess-
ments were then re-administered prior to infusion, on
day 7, at discharge, and on days 14, 30, and 90. For the
purposes of this report, the data related to the neuro-
logical findings, GCS, and 3MS are reported.
Each of the physicians who performed the neurological
examination was trained by a lead neurologist (J.H.) with ex-
perience and expertise in training research study personnel.
The training consisted of reviewing the neurological exam-
ination with the physicians in a group session, supervising
their practicing and performance of the examination, sup-
plying the physicians with detailed instructions on perform-
ing and scoring the neurological examination, and supplying
an instructional video for reference. Refresher training ses-
sions were held annually.
Neurological assessments
For the purposes of this report, the first and last available
time points of testing for each individual were analyzed.
Given the heterogeneity of the neurological findings, the
results of the studies were categorized as follows:
1. The Glascow Coma Scale (GCS) was performed to
determine the patient’s level of consciousness at
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entry. If the patient was in coma, as indicated by a
GCS of 8 or less, the other measures could not be
reliably assessed in most cases and these were noted
as not testable (e.g., 3MS, strength, etc.).
2. The Modified Mini-Mental Status Test evaluated
cognitive performance. A score of 78 or less out of
100 was categorized as impaired [27].
3. The presence of a cranial neuropathy was evaluated
by assessing pupil size, pupillary response, visual
fields to threat, extraocular movements, ptosis, smile
for facial strength, gag reflex, and tongue deviation.
4. Tremors. The presence of tremors and the number
of involved limbs and/or head were noted.
Evaluators also recorded the presence of intention
tremors vs. resting tremors.
5. Weakness. The number of limbs that were weak, the
strength rating using the MRC 5 point strength
scale, and muscle tone were documented. Reflexes
were also recorded. The strength ratings typically
noted were 0, 3, 4, or 5. Muscle tone and reflexes
were correlated with observed limb strength to see if
the typical upper motor neuron (UMN) or lower
motor neuron (LMN) patterns were present.
To facilitate analysis of the dataset, the number of
limbs that were weak was noted and the strength scores
of all of the muscle groups (deltoid, biceps, triceps, bra-
chioradialis, wrist extensors, wrist flexors, and grip for
the upper extremity [UE]; hip flexors, quadriceps, ham-
strings, foot dorsiflexors, and foot plantar flexors for the
lower extremity [LE]) were averaged to provide a limb
strength score.
Neurologic scoring
For each patient, a score was determined at enrollment
and again on follow-up. With the exception of those
consistently in a coma, the Outcome Score ranged from
0 (no cognitive deficits, no tremor, no cranial nerve
problems, no weakness) to 6. One point was awarded for
each deficit.
Biostatistical considerations
This was a randomized, placebo-controlled, multicenter
trial designed to assess and characterize the safety and
tolerability of Omr-IgG-am™ in a population of hospital-
ized patients with confirmed or suspected WNV disease.
Confirmed patients were those who met protocol inclu-
sion/exclusion criteria and had a positive WNV IgM
serologic result from CSF and/or serum. All subjects in-
cluded in this analysis are confirmed cases. The primary
endpoint was to evaluate safety in the group receiving
Omr-IgG-am™ versus the groups receiving conventional
IVIg or placebo (normal saline), as defined by the number
of serious adverse events. Secondary endpoints included
pharmacokinetics of specific anti-WNV antibodies, mor-
tality, and morbidity based on neurological evaluations,
which are described above. A total of 100 patients was
projected to receive investigational therapy with Omr-
IgG-am™ (0.5 g/kg) or one of two controls: IVIG (Poly-
gam® S/D) or normal saline at a 3:1:1 randomization ratio
in order to achieve a reasonable estimation of the treat-
ment related serious adverse event with 95% confidence
intervals. However, this study was terminated early (for
reasons discussed above) with a total of 64 subjects en-
rolled; 2 subjects were determined to be ineligible and re-
ceived no study medication. For the purposes of this
report, the data related to the neurological findings, GCS,
and 3MS are reported to the subgroup of subjects (n = 55
of 62) confirmed to have WNV infection. WNV IgM was
positive (serum and/or CSF) in 55/55; WNV IgG was
positive in serum in 53/55 subjects. Both baseline (day 0)
and the last follow up (day 90) neurological assessment
were examined.
Data are presented using descriptive statistics. Normally-
distributed variables will be reported as means with stand-
ard deviations; non-normally distributed continuous
variables will be reported as medians with ranges; cat-
egorical data is reported as frequency and proportion.
Cochran-Mantel-Haenszel Statistics or Fisher’s exact
were used to exam the association for categorical vari-
ables. Logistic regression analysis and other linear re-
gression analyses were used to evaluate associations
between patients’ demographics and outcomes. These
statistical analyses are exploratory. Statistical analysis
is performed using SAS 9.3 software.
Results
Demographic characteristics
A total of 64 subjects were enrolled into a controlled, ran-
domized study of WNV immune globulin therapy for pa-
tients with WNV neuroinvasive disease. Nine subjects
were subsequently excluded for failing to meet study entry
criteria. Subjects were enrolled at 24 sites; the largest
numbers of subjects were recruited at Idaho Falls, ID (9),
Fargo, ND (6), University of Colorado at Denver, CO (6),
and the University of New Mexico, Albuquerque, NM (6).
The first subject was enrolled on September 21, 2003 and
the last subject enrolled on September 28, 2006.
The median age of the study population was 59 years
(range 34–85 years) and did not vary significantly among
treatment groups. The study population was 72.7% Cau-
casian, 3.6% Black, 18.2% Hispanic, 3.6% Native Ameri-
can, and 1.8% other. Subjects were 69.1% male and
30.9% female. The demographic characteristics for the
three study populations are presented in Table 1.
No subjects were terminated from the study due to
non-fatal adverse events. Death (N = 7) was the most fre-
quent reason for early study termination. For these 7
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subjects, the last evaluation day was as follows: 3 were at
day 7, 3 at day 14, and 1 at day 30.
Treatment effects
Analyses of treatment effects from the clinical trial will
be summarized only briefly to justify merger of treat-
ment groups for this analysis; detailed analysis of the
treatment effects will be published elsewhere.
The primary endpoint for the study was safety in the
experimental drug arm versus each of the 2 control
arms, as determined by the total number of serious ad-
verse events (SAEs). The differences in frequency of
SAEs among the 3 treatment groups were not statisti-
cally significant. Specifically, there were no differences in
neurological SAEs among the 3 treatment groups.
As an indicator of therapeutic efficacy, a combined end-
point of mortality and morbidity was calculated among
confirmed subjects, as assessed by 4 scoring systems
(the Barthel Index, the MRS, the GOS, and the 3MS)
at 3 months in the experimental treatment group ver-
sus 2 control groups. Each subject was placed into one
of 4 functional categories, using pre-defined break-
points: normal, mildly/moderately impaired, severely
impaired, or dead. There were no statistically signifi-
cant differences in the proportions of patients falling
into the 4 functional categories for the 3 treatment co-
horts. Outcomes were further dichotomized into “favor-
able” and “unfavorable” categories using predetermined
cut-points. Exact 95% confidence intervals on the propor-
tion of study participants with an unfavorable outcome
were computed for each treatment arm. The odds ratio
and its 95% confidence interval of favorable outcome be-
tween the experimental arm and each control arm were
also calculated. The favorable versus unfavorable dichoto-
mies for each of the 4 test instruments were also assessed.
Again, no statistically significant differences in the propor-
tion of patients having an unfavorable outcome were
noted among the 3 treatment groups. Thus, we are report-
ing on pooled neurologic data for all 55 of the subjects




The analyses in this report are focused on the subjects
(n = 55) confirmed to have WNV disease by positive
WNV IgM in serum and/or CSF. Neurological score at
both baseline (day 0; n = 55) and those with a last follow-
up at day 90 (n = 48) were assessed.
Overall, the predominant neurological impairments in
these patients were coma, cognitive impairment, cranial
neuropathy, tremor, and/or weakness, in multiple com-
binations (Table 2). The analyses focused on assessing
these variables.
The sensory and reflex examinations were found to be
non-informative to the analysis and somewhat less con-
sistent than the other findings. The measures of finger-
to-nose and heel-to-shin ataxia were typically consistent
and associated with measures of 3-4/5 weakness in the
limbs noted to have ataxia. Thus, there were not reports
of isolated ataxia without associated weakness, resulting
in an inability to confidently report on ataxia.
The most frequent detected cranial neuropathies were
manifested as facial weakness, and these were noted in
the analysis for the presence/absence of impaired cranial
nerve function. Intention tremors were uncommon and
Table 1 The demographic characteristics for the three study populations
Omr-IgG-AM
WNV (N=33) (%)
POLYGAM WNV (N=11) (%) SALINE WNV (N=11) (%) Total WNV (N=55) (%)
Race
Caucasian/Not Hispanic 22 (66.7) 9 (81.8) 9 (81.8) 40 (72.7)
Black/Not Hispanic 1 (3.0) - 1 (9.1) 2 (3.6)
Hispanic 8 (24.2) 1 (9.1) 1 (9.1) 10 (18.2)
Asian or Pacific Islander - - - -
American Indian or Native American 1 (3.0) 1 (9.1) - 2 (3.6)
Other 1 (3.0) - - 1 (1.8)
Gender
Male 23 (69.7) 7 (63.6) 8 (72.7) 38 (69.1)
Female 10 (30.3) 4 (36.4) 3 (27.3) 17 (30.9)
Age in Year
Mean ± SE 58.00 ± 2.18 55.36 ± 4.26 62.18 ± 4.83 58.31 ± 1.82
Median 56 54 60 59
Min-Max 34 - 83 34 - 77 36 - 85 34 - 85
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were typically associated with limb weakness. While there
was no strong correlation between report of an intention
tremor and the report of tremors in general, it cannot be
safely assumed that these were resting tremors, as not all
these patients were assessed by experienced neurologists.
Thus, we will report on tremors, not otherwise further
characterized.
Neurologic outcomes
Descriptive results of the following key variables and their
patterns of impairment in the pre- and post-assessments
are summarized in Table 2.
Table 2 defines the numbers of individuals both at the
first evaluation (baseline) and follow-up who exhibited
the defined neurological deficits, with those individuals
exhibiting multiple deficits listed cumulatively. The pat-
terns of weakness were subdivided for each individual.
Overall, 93% of the patients presented with a neuro-
logical deficit, with 25% of the total cohort presenting
with coma, and 45% with cognitive impairment, result-
ing in 70% of all patients presenting with some form of
alteration in consciousness/cognitive function. In addition,
49% presented with some form of weakness, 35% with
tremor, and 16% with cranial neuropathy.
Seven of the 55 WNV confirmed patients died during
the study (mortality rate of 13%; 6 before day 90 evalu-
ation and one after day 90). Five of those patients were
in a coma upon entry into the study, and the other two
had cognitive impairment and generalized weakness.
Three of the patients who died succumbed to secondary
respiratory complications, two died of cardiac complica-
tions, and two presented in a coma with flaccid quadri-
paresis requiring intubation and their families subsequently
withdrew care. The median age at death was 71 years and
all were Caucasian. Five of those patients were men and
two were women.
Overall, most initially-evident deficits improved, ex-
cept for weakness. However, the profile of the weakness
in individuals changed such that, over time, fewer limbs
were affected and the degree of strength impairment
was reduced.
Tables 3 and 4 report the symptom profiles and num-
bers of individuals with these patterns of deficits for both
the initial presentation (Table 3) and follow-up (Table 4).
Considering the range of profound deficits noted
across subjects, it was notable that four of the 55 (7%)
subjects in the group were found to be normal at onset
and all of these remained normal throughout the study.
By the end of the study, another 14 had returned to nor-
mal in all domains (33% of those who started the study).
Of those who returned to a normal baseline, only two
were initially in a coma, three initially had an isolated cog-
nitive impairment, one initially had an isolated tremor, 3
had general weakness, and 5 had multiple domains of
deficits.
Cross-sectional analyses of demographic characteristics
Gender
Thirty percent of the sample population were female
and, at the initial evaluation, approximately one-third of
them were in a coma. Only one of the four women
(25%) who were comatose at presentation was not in a
coma 90 days later. Notably, eight of the 10 males (80%)
who were comatose at presentation were not in coma
90 days later.
Ethnicity
None of the African-Americans (N = 2) or Hispanics
(N = 10) presented in a coma, whereas all of the Native
Americans (N = 2) presented clinically in a coma (p = .01).
Of the subjects who could cooperate for strength testing
at long-term follow-up at 90 days (N = 48), Caucasians
Table 2 Symptoms at initial and follow-up clinical presentation
Initial evaluation (N = 55) Normal Coma Cognitive impairment Cranial neuropathy Tremor Weakness





Follow-up Evaluation (N = 48) Normal Coma Cognitive impairment Cranial neuropathy Tremor Weakness






When an individual had multiple deficits, they are listed above multiple times under each deficit they possessed at that time.
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were over-represented in the generalized 4-limb weakness
group, whereas Hispanics were over-represented in the
2-limb category and underrepresented in the 4-limb
category (p = .01).
Age
The effect of age on weakness measured in those who
could cooperate for testing at day 90 (N = 48) showed a
trend whereby older patients were more likely to exhibit
weakness. There was a trend toward an over-representation
of weakness in the more severely impaired ranges (p = .08).
Using age (by decade) as a predictor in a linear regression,
one could reliably predict the degree of a weakness deficit
(p = .01, R2 = .132). Actual age as the predictor in the linear
regression also reliably predicted the degree of weakness
deficit (p = .03, R2 = .101). There was no relationship be-
tween age and degree of weakness reported at the onset of
the study (chi-squared and linear regression, p > .80).
Longitudinal analyses of factors
We subtracted the Outcome Scores (range of 0–6 on
mortality and main neurological outcome factors) from
those at the initial evaluation. These scores were assessed
across all neurologic factors using chi-square statistics.
Ethnicity did not show the expected distribution related to
resolution of coma, p = .001. At the onset of the study, 11
of the 40 Caucasian, both of the 2 Native American, and 1
of the ‘Other” ethnicity subjects were in a coma. None of
the 10 Hispanic or 2 African-American subjects was in a
coma at the onset of the study. At follow-up evaluation,
only 1 (Caucasian) of the 14 (N = 55 at beginning of study)
patients remained in a coma, 8 recovered from coma, and
5 were dead (all Caucasian).
Assessing the change scores for the coma condition,
those who were in a coma at presentation, but not at
Day 90, were more likely to have a cognitive deficit at
the termination of the study (p = .01).
As noted above, we calculated an Outcome Score from
0 (no coma, no cognitive deficits, no tremor, no cranial
nerve problems, no weakness) to 5, with death being a
score of 6 (N = 55). Age decade reliably predicted this
Outcome Score (p = .04). Initial presentation in a coma also
was a significant factor in predicting outcome (p < .0001).
Those in a coma at presentation were more likely to have a
cognitive deficit at the end of the study (p = .01).
Table 4 Follow-up clinical profiles (N = 48)
Normal 19
Coma 1








Asymmetric limb paresis + facial weakness + dysconjugate gaze 1
Asymmetric limb paresis + facial weakness 1
Asymmetric limb paresis + tremor 1
Impaired cognition + tremor + general weakness 2
Impaired cognition + tremor + facial weakness 1
Impaired cognition + general + facial weakness 1
Impaired cognition + tremor + hemiparesis 1
Impaired cognition + tremor + asymmetric limb paresis 2
Impaired cognition + hemiparesis 1
Tremor + UEs weak 1
UEs: upper extremities.
Table 3 Initial clinical profiles (N = 55)
Normal 4
Coma 14








Asymmetric limb paresis 2
Bilateral UEs 1
Asymmetric limb paresis + facial weakness +
dysconjugate gaze
1
General + facial weakness + dysconjugate gaze 1
Facial weakness + decreased gag reflex 1
Impaired cognition + tremor + general
weakness
5
Impaired cognition + tremor + general
weakness + dysconjugate gaze/pupil reactivity
1
Impaired cognition + tremor + asymmetric
limb paresis
1
Impaired cognition + tremor + paraparesis 1
Impaired cognition + general weakness 9 (with 3 of these
w/facial weakness)
Impaired cognition + UEs weak 1
Impaired cognition + tremor 2
Tremor + facial weakness + decreased
gag reflex
1
Tremor + general weakness 1
UEs: upper extremities.
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Regression analysis of outcome scores
A logistic regression initially yielded no significant results,
so the presentation values were changed to continuous
variables and a multiple regression analysis was performed
to predict the Outcome Score. Stepwise regression re-
vealed that only coma at Day 1 and cranial nerve path-
ology at Day 1 made unique contributions to the model,
accounting for 33.2% of the variance in Outcome Score
(p < .0001). Coma at Day 1 reliably predicted the Outcome
Score when used as the sole regressor, R2 = .278, p < .0001.
The model was significantly improved by adding cra-
nial nerve pathology at Day 1 as a predictor, R2 = .332,
p = .0463. Cognitive deficit at Day 1 trended toward
significantly improving the model (R2 change .038, p = .084).
None of the other predictors significantly improved the
model (p > .25).
Discussion
This study reports neurologic outcome data derived from
a multicenter therapeutic trial involving patients with neu-
roinvasive WNV disease. The wide spectrum of neuro-
logic impairments in these patients was similar to what
has been reported in previous studies. The patients pre-
sented with a combination of deficits that included coma,
mental status, cranial neuropathy, tremor, and/or weak-
ness (including asymmetric limb weakness). This repre-
sents one of the largest studies providing prospectively
acquired neurological outcomes data among American
patients with WNV CNS disease.
The initial presentation of patients with WNV enceph-
alitis and/or myelitis in this study demonstrated several
salient characteristics of the neurological profile associ-
ated with this disease. Across all patients (n = 55), 93%
presented with a significant neurological deficit detect-
able by clinical examination, with 49% having some form
of weakness, 35% with tremor, and 16% with cranial
neuropathy. Also included in the initial clinical profiles
were five patients with isolated cognitive impairment as
measured by the 3MS, one with tremor only, and six
with weakness only, including two with single limb and
one with bilateral arm weakness. Presentation with just
these isolated findings not only points out the selective
clinical features with which this viral infection can mani-
fest, but also provides insight into the brain structures
the virus may affect. To account for the cranial neuropa-
thies and also for coma, brain stem involvement is impli-
cated. Pathological processes affecting the basal ganglia
and/or thalamus can result in cognitive impairments,
tremors, coma, and/or generalized weakness. Asymmet-
ric limb weakness has been classically associated with in-
fection by polio virus, a picornavirus that affects the
anterior horn cells of the spinal cord [28]. WNV plaus-
ibly affects the same cell populations in those patients
who exhibit a similar pattern of neurological deficits.
Seven patients died after initial enrollment in the study.
The number of deaths is too small to provide a clear pat-
tern of those who are at most risk, but it is clear that pre-
senting in a coma early was common in this selected
population (5 of the 7). However, 14 patients presented in
a coma, so not all who present in a coma have such a poor
prognosis. In our study, these patients tend to be older in
general (mean age at death approximately 65 years) than
other subjects, Caucasian (all), and male (5 of 7 patients);
however, there are individuals with similar profiles who
experience some degree of recovery.
Despite the lack of specific treatment of proven value
for WNV neuroinvasive disease, considerable natural re-
covery occurs. Overall, there were 14 comatose subjects
at baseline evaluation, but only one at follow-up. The
number of patients who exhibited a cognitive deficit fell
from 25 at initial evaluation to 9 at their last evaluation.
Cranial neuropathy was present in 9 at onset and only 4
patients at study conclusion. Of the 19 who initially had
a tremor at enrollment, 11 continued to exhibit a tremor
at follow-up.
Previous reports have described asymmetric limb par-
esis (similar to those reported with poliomyelitis), gener-
alized weakness, paraparesis, and hemiparesis. We observed
considerable evolution in the type as well as numbers with
weakness. Some aspects of these changes were likely
accounted for by resolution of impaired cognition, includ-
ing coma, which allowed for a more complete and reliable
evaluation of limb strength among other clinical findings.
Whereas at onset there were 20 patients with generalized
weakness and 4 with asymmetric limb weakness, 1 para-
paresis, 2 upper extremity weakness, and none with hemi-
paresis, there were considerably more individuals with
clearly defined, focal weakness (6 generalized weakness, 7
asymmetric limb weakness, 2 with UE weakness, 4 para-
paresis, and 4 hemiparesis) at follow-up.
There are several factors that predict either severity of
a patient’s initial deficits or probability of long-term re-
covery. While ethnicity appeared to be associated with
patients’ deficits, interpretation of the findings is limited
by the small numbers of patients in each group. Males
more often resolved from an initial state of coma than
did women. Initial presentation in a coma also was a sig-
nificant factor in predicting outcome. In fact, initial
presentation in a coma and cranial nerve deficits best
predict the overall neurological outcome score at three
months after enrollment. These same factors also predict
whether a patient will have a cognitive deficit at follow-up.
Coma and cranial nerve deficits in combination not only
suggest significant neurological impairment, but also sug-
gest the effect of the virus on the brainstem (or possibly
additional thalamic involvement), which appears to predis-
pose an individual to a poorer long-term outcome. Age is
also a predictive factor for weakness at follow-up.
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Several limitations in this study are worth noting. One
of the key limitations is that the examinations were per-
formed by different examiners, most of whom were in-
ternists/infectious diseases specialists, not neurologists.
Another drawback to the study is the relatively small
number of subjects, even though this is among the lar-
gest cohorts of prospectively followed patients reported
to date. Given the unpredictable nature of the WNV
outbreaks, the present study design was utilized to capture
the largest number of patients for initial and follow-up
evaluations, but subject recruitment was still very challen-
ging. Study modifications that allow for more rapid and
flexible subject recruitment (including use of a universal
Institutional Review Board) in the earliest stages of an out-
break would likely increase the number of patients en-
rolled and expand the type of investigative tools that could
be utilized (e.g., neuroimaging, EMG, etc.).
Prognostic determinations in previous studies have not
included formal neurological evaluation or use of the
3MS administered to subjects to assess functional status.
Prognosis with measures such as the Short Form 36 [29]
have reported a ‘favorable’ outcome in most patients
after one year in the typical patient, providing an esti-
mate of when recovery asymptotes [30]. In contrast, a
telephone follow-up of symptom presence and severity
of neurological status suggested only 37% achieved a full
recovery at 1 year, with older age being a significant
negative predictor [25]. Another survey of 214 patients
7 months after their acute illness found that age and
gender were not associated with persistent symptoms
[31], which is contrast to our findings. Self-reported symp-
toms in conjunction with neurological assessment ap-
proximately a year after the acute illness revealed a variety
of somatic, neurological, and cognitive complaints with 10
of 49 reporting tremor and one patient with asymmetric
paralysis [24]. In the present study, there was a much
wider array of neurological deficits detected at long-term
follow-up examination and a higher percentage of individ-
uals with deficits, arguing for formal neurological evalua-
tions to most accurately assess neurological outcomes.
Given the limitations in this study, we chose the neuro-
logical measures in our analysis by reviewing the measures
collected and finding the most consistent data that could
be confirmed by converging scores from other measures
(e.g., strength measures for limbs supported by multiple
strength measures for muscle groups). Thus, limb strength
is reported as an overall measure, which is not as precise
as desirable. These WNV outbreaks do not produce a
purely random sample, and the examinations also lacked
corroborative imaging and/or electrophysiological studies
due to study and site limitations. Finally, we collapsed 3
cohorts from a treatment trial to report this ‘natural his-
tory’ study since the treatment was found to be ineffective.
These caveats notwithstanding, the present study provides
one of the largest cross-sectional and longitudinal charac-
terizations of the neurological deficits encountered in sub-
jects with WNV neuroinvasive disease.
Conclusion
This study represents one of the largest clinical investi-
gations providing prospectively- acquired neurological
outcomes data among American patients with WNV CNS
disease. At initial clinical presentation (n = 55), 93% pre-
sented with a significant neurological deficit detectable by
clinical examination, with 49% having some form of weak-
ness, 35% with tremor, and 16% with cranial neuropathy.
Also included in the initial clinical profiles were five pa-
tients with isolated cognitive impairment as measured by
the 3MS, one with tremor only, and six with weakness
only, including two with single limb and one with bilateral
arm weakness. Seven patients died after initial enrollment
in the study, with presentation in a coma being common
in this subgroup (5 of the 7). In terms of long-term
follow-up, 14 subjects presented in a coma at baseline
evaluation, while only one of the survivors remained in a
coma at final follow-up. The number of patients who ex-
hibited a cognitive deficit fell from 25 at initial evaluation
to 9 at their last evaluation. Cranial neuropathy was
present in 9 at onset and only 4 patients at study conclu-
sion. Of the 19 who initially had a tremor at enrollment,
11 continued to exhibit a tremor at follow-up.
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